Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that ER positive status confers therapeutic sensitivity to Tamoxifen in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved tamoxifen for reimbursement as a treatment option for the adjuvant treatment of estrogen receptor positive breast cancer in patients who are pre- or post-menopausal women.

This statement is based on a regulatory approval from the Health Service Executive:

Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.

Citation

Tamoxifen Monotherapy, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6357/253_v5_Tamoxifen_Monotherapy.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-11-01	Health Service Executive	Indication approved for reimbursement.